DAOA variants and schizophrenia: Influence on diagnosis and treatment outcomes

Alberto Chiesa, Chi Un Pae, Stefano Porcelli, Changsu Han, Soo Jung Lee, Ashwin A. Patkar, Moon Ho Park, Alessandro Serretti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective. The present study explored whether d-amino acid oxidase activator (DAOA) variants were associated with schizophrenia and whether they could predict the clinical outcomes of patients treated with various antipsychotics. Methods. Two hundred and twenty-one (221) patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for seven DAOA single-nucleotide polymorphisms (SNPs) (rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571 and rs778293). We also administered baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), to patients with schizophrenia. Results. None of the SNPs under investigation was associated with the development of schizophrenia. However, the rs7139958 AA and rs9558571 TT as well as the rs7139958 A and rs9558571 T genotypes were associated with higher scores on the PANSS positive subscale among patients with schizophrenia, possibly reflecting their greater susceptibility to the development of more severe positive symptoms. No other allele, genotype, or haplotype under investigation was significantly associated with any of the clinical parameters, including clinical improvement, in patients with schizophrenia. Conclusion. Our results suggested that rs7139958 and rs9558571 SNPs may be associated with more severe baseline positive symptoms in patients with schizophrenia. However, further research is needed to draw more definitive conclusions given the limitations of our study.

Original languageEnglish
Pages (from-to)303-310
Number of pages8
JournalInternational Journal of Psychiatry in Clinical Practice
Volume15
Issue number4
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Schizophrenia
Oxidoreductases
Amino Acids
Single Nucleotide Polymorphism
Genotype
Haplotypes
Antipsychotic Agents
Alleles
Research

Keywords

  • clinical improvement
  • DAOA
  • schizophrenia
  • treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

DAOA variants and schizophrenia : Influence on diagnosis and treatment outcomes. / Chiesa, Alberto; Pae, Chi Un; Porcelli, Stefano; Han, Changsu; Lee, Soo Jung; Patkar, Ashwin A.; Park, Moon Ho; Serretti, Alessandro.

In: International Journal of Psychiatry in Clinical Practice, Vol. 15, No. 4, 01.11.2011, p. 303-310.

Research output: Contribution to journalArticle

Chiesa, Alberto ; Pae, Chi Un ; Porcelli, Stefano ; Han, Changsu ; Lee, Soo Jung ; Patkar, Ashwin A. ; Park, Moon Ho ; Serretti, Alessandro. / DAOA variants and schizophrenia : Influence on diagnosis and treatment outcomes. In: International Journal of Psychiatry in Clinical Practice. 2011 ; Vol. 15, No. 4. pp. 303-310.
@article{5561eff7e80c4a64aa342d1eae7415d1,
title = "DAOA variants and schizophrenia: Influence on diagnosis and treatment outcomes",
abstract = "Objective. The present study explored whether d-amino acid oxidase activator (DAOA) variants were associated with schizophrenia and whether they could predict the clinical outcomes of patients treated with various antipsychotics. Methods. Two hundred and twenty-one (221) patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for seven DAOA single-nucleotide polymorphisms (SNPs) (rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571 and rs778293). We also administered baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), to patients with schizophrenia. Results. None of the SNPs under investigation was associated with the development of schizophrenia. However, the rs7139958 AA and rs9558571 TT as well as the rs7139958 A and rs9558571 T genotypes were associated with higher scores on the PANSS positive subscale among patients with schizophrenia, possibly reflecting their greater susceptibility to the development of more severe positive symptoms. No other allele, genotype, or haplotype under investigation was significantly associated with any of the clinical parameters, including clinical improvement, in patients with schizophrenia. Conclusion. Our results suggested that rs7139958 and rs9558571 SNPs may be associated with more severe baseline positive symptoms in patients with schizophrenia. However, further research is needed to draw more definitive conclusions given the limitations of our study.",
keywords = "clinical improvement, DAOA, schizophrenia, treatment response",
author = "Alberto Chiesa and Pae, {Chi Un} and Stefano Porcelli and Changsu Han and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Park, {Moon Ho} and Alessandro Serretti",
year = "2011",
month = "11",
day = "1",
doi = "10.3109/13651501.2011.589518",
language = "English",
volume = "15",
pages = "303--310",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - DAOA variants and schizophrenia

T2 - Influence on diagnosis and treatment outcomes

AU - Chiesa, Alberto

AU - Pae, Chi Un

AU - Porcelli, Stefano

AU - Han, Changsu

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Park, Moon Ho

AU - Serretti, Alessandro

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objective. The present study explored whether d-amino acid oxidase activator (DAOA) variants were associated with schizophrenia and whether they could predict the clinical outcomes of patients treated with various antipsychotics. Methods. Two hundred and twenty-one (221) patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for seven DAOA single-nucleotide polymorphisms (SNPs) (rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571 and rs778293). We also administered baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), to patients with schizophrenia. Results. None of the SNPs under investigation was associated with the development of schizophrenia. However, the rs7139958 AA and rs9558571 TT as well as the rs7139958 A and rs9558571 T genotypes were associated with higher scores on the PANSS positive subscale among patients with schizophrenia, possibly reflecting their greater susceptibility to the development of more severe positive symptoms. No other allele, genotype, or haplotype under investigation was significantly associated with any of the clinical parameters, including clinical improvement, in patients with schizophrenia. Conclusion. Our results suggested that rs7139958 and rs9558571 SNPs may be associated with more severe baseline positive symptoms in patients with schizophrenia. However, further research is needed to draw more definitive conclusions given the limitations of our study.

AB - Objective. The present study explored whether d-amino acid oxidase activator (DAOA) variants were associated with schizophrenia and whether they could predict the clinical outcomes of patients treated with various antipsychotics. Methods. Two hundred and twenty-one (221) patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for seven DAOA single-nucleotide polymorphisms (SNPs) (rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571 and rs778293). We also administered baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), to patients with schizophrenia. Results. None of the SNPs under investigation was associated with the development of schizophrenia. However, the rs7139958 AA and rs9558571 TT as well as the rs7139958 A and rs9558571 T genotypes were associated with higher scores on the PANSS positive subscale among patients with schizophrenia, possibly reflecting their greater susceptibility to the development of more severe positive symptoms. No other allele, genotype, or haplotype under investigation was significantly associated with any of the clinical parameters, including clinical improvement, in patients with schizophrenia. Conclusion. Our results suggested that rs7139958 and rs9558571 SNPs may be associated with more severe baseline positive symptoms in patients with schizophrenia. However, further research is needed to draw more definitive conclusions given the limitations of our study.

KW - clinical improvement

KW - DAOA

KW - schizophrenia

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=80053989463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053989463&partnerID=8YFLogxK

U2 - 10.3109/13651501.2011.589518

DO - 10.3109/13651501.2011.589518

M3 - Article

C2 - 22122005

AN - SCOPUS:80053989463

VL - 15

SP - 303

EP - 310

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 4

ER -